spacer
home > ebr > Winter 2012
PUBLICATIONS

European Biopharmaceutical Review

ebr
Winter 2012

European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America & the rest of the world.

With editorial consisting of in-depth articles, case studies, meeting and report reviews written by specialists with hands-on experience in the biopharmaceutical industry, traditional multi-national pharmaceutical companies, investment houses and industry-associated governmental, economic and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with regular feature sections on BioBusiness Development, Research and Innovation, BioDiscovery, BioManufacturing plus special focuses on geographic or therapeutic territories.

   
Text
PDF
BioBusiness, Finance & Communication

Biogenerics

A Fork in the Road

A Fork in the RoadWhile some fear the looming presence of the patent  cliff, it does offer the biopharma industry a new marketfor ‘follow-on’ biologics and the promise of a new revenue source in the guise of biosuperiors and biosimilars. Herren Wu at MedImmune weighs up the risks and benefits of each, and asks whether it’s enough to be equal.
 
view
download pdf

Strategies for Growth: M&A

Preparing to Succeed

As Big Pharma seeks to boost its portfolios in a diffi cult climate, it is important for biotechs to proactively position themselves for potential M&A events. Erik Lundh at J. Robert Scott Executive Search outlines key leadership strategies for capitalising on these opportunities.

 
view
download pdf
Strategies for Growth: Biopartnering

Canny Collaborations

Diminishing profit margins and rocketing drug development costs are starting to worry Big Pharma. However, Robert Lee Kilpatrick of TVG LLC argues that the partnering opportunities this climate brings hold the key to the industry’s survival and continued innovation.
 
view
download pdf
bullet
Business Development and Financing

Outsourcing Language Services

Write on Target

Scientific writing can pose a challenge, requiring high academic standards aimed at a range of target groups. Simone Lamont and Reto Schlegel at CLS Communication AG look at the benefits of outsourcing to a dedicated team of specialists, and consider what makes a successful communication project.

 

 
view
download pdf
bullet
BioResearch and Innovation

Vaccine Development

Protein on the Fly

Wian De Jongh at ExpreS2ion Biotechnologies and Ali Salanti of the Centre for Medical Parasitology, University of Copenhagen, examine the challenges of developing a vaccine for placental malaria, and the possibility of using insect cell systems for manufacturing a protein-based solution.

 
view
download pdf
Anti-Aggregation Therapeutics

Tackling Toxics

Therapies that target toxic Aβ assemblies hold the potential to revolutionise the treatment of Alzheimer’s disease. Mark Treherne and David Scopes of Senexis examine developments in this field, and weigh up the benefits of different structural approaches.
 
view
download pdf
Biomarker Discovery: Psychiatric Health

Diagnosing Schizophrenia

Sabine Bahn and Paul C Guest at the Cambridge Centre for Neuropsychiatric Research at Cambridge University investigate the role biomarkers could play in diagnosing psychiatric disorders, and the challenges of translating recent discoveries into a blood-based test for clinical use.
 
view
download pdf
Agricultural Biotechnology

Natural Potential

The use of plants in protein production has been widely reported, but the broader possibilities of agricultural biotechnology are only just beginning to make their mark. Gwyn Riddick of the North Carolina Biotechnology Center considers how this rapidly developing field may one day feed, heal and power the world.
 
view
download pdf
bullet
Discovery Technology

Biomarker Discovery: Analytical Software

Analyse This

Biomarkers hold huge potential for oncology, paving the way for personalised therapies. Carl-Johan Ivarsson at Qlucore explores the technologies available that can visualise the genomic signatures of cancer cells and so aid biomarker discovery.

 
view
download pdf

Benchtop Bioreactors

Causing a Stir

As the market for biologics continues to grow, advanced benchtop bioreactors can change the way biomanufacturers standardise and streamline process development. Kathrin Schmale and Karl Rix at DASGIP discuss the factors to consider when selecting a bioreactor.

 
view
download pdf
Optical Sensors: Biofermentation

Measurable Advances

Rob Morris, Mahmoud Shahriari, Harish Dabhi and Derek Guenther of Ocean Optics present current developments in fibre optic sensors capable of measuring oxygen distribution, and the uses they can have when analysing bioreactor processes.
 
view
download pdf
Optical Sensors: Tissue

Oxygen in Action

As well analysing bioreactor processes, analyte mapping in 2D can give a detailed picture of oxygen distributions within skin, flesh and bone samples. Gregor Liebsch at PreSens Precision Sensing GmbH looks at applications in a range of tissues.
 
view
download pdf
bullet
BioDevelopment and Regulatory

Antimicrobial Therapeutics

Top Class Templates

As global infection rates increase, so does the market for anti-infectives. Deborah A O’Neil at NovaBiotics Ltd champions peptides as an ideal therapeutic template, with advances in peptide synthesis making them a commercially attractive option for a new class of antimicrobials.

 
view
download pdf
European Patent Law

Stemmed Potential

Philip Webber at Dehns Patent and Trade Mark Attorneys considers the complex relationship between science, law and ethics that informed a recent ruling on patenting inventions in the area of human embryo research, and considers the possible impact this may have on stem cell research.
 
view
download pdf
Regulatory Changes

Off the Beaten Track

Advanced therapy medicinal products is the latest health product category to be established by the European Commission. Christian van den Bos at Lonza analyses the evolution of the regulatory path for cell, tissue and gene therapies, and what this means for the approval and clinical trial process.
 
view
download pdf
bullet
Biodevelopment and Manufacturing
Biomanufacturing

Learning Curve

Susan Dana Jones and Howard L Levine of BioProcess Technology Consultants, and Susan McKee of Angel Biotechnology explore how lessons from the early days of monoclonal antibody development can help guide advances in cell therapeutics.
 
view
download pdf
bullet
BioFormulation and Manufacturing
Bioconjugates

Conjugation Ahead

Synthetically produced peptides and nucleic acids are paving the way for advances in bioconjugates, enabling multiple active molecules to be cross-linked. Miguel Castro at Bio-Synthesis Inc and Dante Marciani at Qantu Therapeutics take a detailed look at bioconjugate variations, and the opportunities these open up for gene therapy.
 
view
download pdf
Outsourcing Strategies

Take Your Pick

Outsourcing part or all of the supply chain is often a necessity for organisations, but managing the relationship with a CMO can be difficult. Peter Calcott at Calcott Consulting outlines the essential elements of a technical or quality agreement that can help ensure a successful partnership.
 
view
download pdf
bullet
BioRegional
Regional Focus: Austria

Budding Biotech

In recent years, the Austrian scene has been a hive of activity for business development. Sonja Polan at Life Science Austria explores why multinationals are looking to the region as a strong source of lead pipeline compounds, technologies and services.
 
view
download pdf
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

Fifth Annual Peptides Congress: Registration Now Open

Join us at the forefront of industry innovation at the 5th Annual Peptides Congress, 16-17 April 2018 in London to shape the future of industry discussion. With over 700 peptides in clinical trials and an increasing industry focus on biologics, now more than ever is the time to focus on this revolutionary field!
More info >>

White Papers

The Promise and Challenge of Adaptive Design in Oncology Trials

Medpace

Clinical oncology trials are more complex and time consuming than those in any other therapeutic area and failure rates are frustratingly high. Given the urgent need for new oncologic therapies, sponsors are eager to find more effective ways to conduct clinical research. Incorporating adaptive design methodologies into clinical trials can reduce costs and enhance efficiency while maintaining trial integrity. They can also reduce the number of patients on placebo and sub-therapeutic doses. In light of this promise, regulatory bodies have created guidelines supportive of adaptive design.
More info >>

Industry Events

14th Annual Biomarkers & Immuno-Oncology World Congress

11-13 June 2018, Westin Boston Waterfront, Boston, Massachusetts

The Biomarkers and Immuno-Oncology World Congress brings together a unique and international mix of large and medium pharmaceutical, biotech and diagnostics companies, leading universities and clinical research institutions, government and national labs, CROs, emerging companies and tool providers—making the Congress a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement